Research theme for competitive and other funds (6)：
2021 - 2024 SHP2による薬剤toleranceを標的とした肺がん根治的治療の開発
2020 - 2024 Examination of radiation pneumonitis using ultra-high definition CT and gene polymorphism
2018 - 2020 治間質性肺炎合併肺癌に対する新規治療戦略の開発-化学予防の観点から-
2015 - 2019 Next generation lung cancer mice model for conquering cancer stem
2016 - 2018 Comprehensive analysis of druggable tyrosine kinase in idiopathic interstitial pneumonia
2007 - 2008 Chemoprevention of Lung Cancer using Epidermal Growth Factor Receptor Transgenic Mice
Show all
Papers (266)：
Naoyuki Nogami, Toshio Kubo, Akihiro Bessho, Makoto Sakugawa, Satoshi Ikeo, Toshihide Yokoyama, Nobuhiko Seki, Ryosuke Ochiai, Nobukazu Fujimoto, Shuji Murakami, et al. A single arm Phase I/II trial on the combination of carboplatin, nab-paclitaxel and avastin as first-line treatment for advanced non-squamous non-small cell lung cancer (TORG1424/OLCSG1402: CARNAVAL). Japanese journal of clinical oncology. 2024
Eiki Ichihara, Nobuaki Ochi, Go Makimoto, Kenichiro Kudo, Daijiro Harada, Yukinori Ozaki, Hiroshi Nishio, Kenji Tsuchihashi, Yuji Miura, Makoto Endo, et al. Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer: a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022. International Journal of Clinical Oncology. 2024. 29. 4. 355-362
Naofumi Hara, Eiki Ichihara, Hirohisa Kano, Chihiro Ando, Ayako Morita, Tatsuya Nishi, Sachi Okawa, Takamasa Nakasuka, Atsuko Hirabae, Masaya Abe, et al. CDK4/6 signaling attenuates the effect of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer. Translational lung cancer research. 2023. 12. 10. 2098-2112
Chihiro Ando, Eiki Ichihara, Tatsuya Nishi, Ayako Morita, Naofumi Hara, Kenji Takada, Takamasa Nakasuka, Hiromi Watanabe, Hirohisa Kano, Kazuya Nishii, et al. Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK-rearranged non-small cell lung cancer. Cancer science. 2023
Toshio Kubo, Eiki Ichihara, Daijiro Harada, Koji Inoue, Keiichi Fujiwara, Sinobu Hosokawa, Daizo Kishino, Haruyuki Kawai, Nobuaki Ochi, Naohiro Oda, et al. Efficacy of immune checkpoint inhibitor monotherapy in elderly patients with non-small-cell lung cancer. Respiratory investigation. 2023. 61. 5. 643-650
中田英二, 藤原智洋, 国定俊之, 尾崎敏文, 平沢晃, 二川摩周, 遠西大輔, 冨田秀太, 久保寿夫, 宮本理史. Genomic medicine and new treatment strategies based on biomarkers for soft tissue sarcoma. 整形・災害外科. 2022. 65. 3
Yuka Kato, Taku Noumi, Kazuhiko Saeki, Kiichiro Ninomiya, Toshio Kubo, Masanori Fujii, Kammei Rai, Eiki Ichihara, Kadoaki Ohashi, Masahiro Tabata, et al. Impact on second-line treatment after failure of immune checkpoint inhibitor (ICI) combination chemotherapy in extensive-disease small cell lung cancer: Experience of the Okayama Lung Cancer Study Group. JOURNAL OF CLINICAL ONCOLOGY. 2021. 39. 15
hase II trial of carboplatin, nab-paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (CARNAVAL study; TORG1424/OLCSG1402)
(ESMO Asia Annual Meeting 2019)
2007 - 2013 Okayama University Graduate School of Medicine , Dentistry and Pharmaceutical Sciences
1996 - 2002 Okayama University Medical School Faculty of Medicine
Professional career (1)：
博士 ( 岡山大学大学院)
Work history (1)：
2013/12 - 現在 Okayama University Hospital Center for Clinical Oncology Assistant Professor
Association Membership(s) (9)：
American Society of Clinical Oncology
, American Association for Cancer Research
, JAPAN SOCIETY FOR PALLIATIVE MEDICINE
, JAPAN SOCIETY OF CLINICAL ONCOLOGY
, JAPAN SOCIETY OF MEDICAL ONCOLOGY
, THE JAPAN SOCIETY FOR RESPIRATORY ENDOSCOPY
, THE JAPAN LUNG CANCER SOCIETY
, THE JAPANESE RESPIRATORY SOCIETY
, THE JAPANESE SOCIETY OF INTERNAL MEDICINE
